諾誠健華-B(09969.HK)年度收益達10.43億元,研發開支增加79.2%至7.22億元
格隆匯3月23日丨諾誠健華-B(09969.HK)發佈公吿,截至2021年12月31日止年度,集團的收益達人民幣10.43億元,而上年度則為人民幣140萬元;成本及開支總額為人民幣13.277億元,而上年度則為人民幣6.645億元,其中研發開支由上年度的人民幣4.028億元增加79.2%至人民幣7.216億元。集團的現金及銀行和理財產品結餘由截至2020年12月31日的人民幣39.696億元,增加65.0%至截至2021年12月31日的人民幣65.505億元。
憑藉集團管理團隊的全球視野及本土專業經驗,集團打造了多樣化及均衡的藥品組合,並於報吿期內推出集團第一款產品奧布替尼。集團的候選藥物均以創新及經驗證的通路為靶點。集團的發現及研發工作致力於經驗證靶點及有潛力成為安全性最高及療效最佳的候選藥物。集團亦致力於發掘新靶點及開發在全球具有突破潛力的療法。
集團正在建立在血液腫瘤領域領先的業務板塊,其中以核心自主開發的奧布替尼作為骨幹療法,以唯一獲美國FDA批准的CD19抗體Tafasitamab用於治療復發難治DLBCL;正在研發涵蓋所有重要的血液腫瘤靶點(例如CD20xCD3、 BCL-2及E-3連接酶)的多種藥物,及在中國建立完善且專注的商業化平台。
在自身免疫性疾病方面,集團與MS領域的全球神經病學領導者渤健合作。近期,集團在中國完成了SLE的II期試驗並取得正面成果,也正積極尋求進一步開發奧布替尼以用於治療SLE。集團還透過II期試驗,探索奧布替尼用於治療ITP及 NMOSD。隨着集團加入兩種TYK2抑制劑(ICP-332及ICP-488),集團具備條件為自身免疫性疾病未被滿足的巨大臨牀需求提供口服藥物解決方案。
在實體瘤領域,集團相信集團的潛在同類最佳分子,靶向FGFR的ICP-192及靶向泛TRK的ICP-723,將使集團能夠建立穩固基礎,同時憑藉迅速增長和日趨成熟的早期在研藥物(包括針對SHP2及CCR8等新靶點的ICP-033、ICP-189、 ICP-B05、ICP-915及ICP-B03),有望於未來能夠為中國及全球各種實體瘤患者提供具競爭力的治療解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.